A correction of misinformation regarding Herbalife

Abstract

The authors of the subject article by Senadhi et al have misrepresented the safety and regulatory status of Herbalife’s products. While we are very concerned with the unwarranted and unfavorable publicity that the inaccuracies listed could generate for Herbalife, we would welcome any inquiries that these authors may have to better clarify our commitment to the safety and quality of our products as has been demonstrated in part by our ability to establish positive relationships with regulatory authorities worldwide through continued cooperation and compliance. This letter clarifies the misinformation presented about Herbalife in the subject article.

Keywords: Hepatitis, Drug-induced liver injury, Herbalife, Herbal, Dietary supplements

Core tip: The authors of the subject article by Senadhi et al have misrepresented the safety and regulatory status of Herbalife’s products. Most importantly, the authors have misinformed the readership that Food and Drug Administration (FDA) has taken action against Herbalife for its known association with reports of liver injury. FDA has taken no action on the company for this reason or any other reasons to date.